The global market for lactose intolerance treatment is expected to reach USD 26.12 billion during the forecast period from 2022-2030, with a CAGR of approximately 5.9%. Several factors collectively influence the dynamics and growth of the lactose intolerance treatment market. The main driver here is the high prevalence of lactose intolerance, a common digestive disorder characterized by the inability to digest lactose – milk sugar. Technological advancements significantly shape the landscape of lactose intolerance treatment. Constant innovation in lactase supplements, diagnosis tools, and improved production technologies for lactose-free foods make treatment more convenient and accessible. Moreover, advanced investigations carried out in the digestion health sector contribute to a better comprehension of mechanisms underlying lactase deficiency, leading to the refinement of targeted interventions.
Economic factors such as healthcare spending and consumer purchasing power also affect market dynamics. This economy-based factor determines whether it would be feasible financially to absorb treatments for lactose intolerance within normal dietary practices. Additionally, geographical variations contribute to shaping this market since different regions face varied challenges in terms of dietary practices related to lactose intolerance. For instance, cultural dietary patterns and levels of awareness about lactase deficiency vary from one region to another, therefore influencing the type or mode of intervention required to address these needs. Despite all these factors, the competitive nature contributes to increased innovations in this sector as well as the expansion of markets in relation to addressing issues related to the lack of enzymes causing intolerant behavior towards the consumption of milk, among others.
Furthermore, awareness drives development, although not as central as economic aspects have been too far-reaching. Initiatives have been made to avoid ignorance regarding who knows what. As knowledge of both symptoms and remedies continues to be absorbed by people, the majority will then seek appropriate medical approaches, which will eventually reflect upon their diets later on. In fact, education programs, including campaigns aimed at building confidence in safety and efficacy in dealing with lactase insufficiency, have provided room for trustworthiness in incorporating these interventions into the lives of lactose-intolerant people.
Report Attribute/Metric | Details |
---|---|
Growth Rate | 5.90% |
Global Lactose Intolerance Treatment Market is expected to register a CAGR of 5.90% during the assessment period of 2023 to 2030 to reach USD 26.12 Billion by 2030.
India's leading food and milk firm, Drupe Food India, launched Lactose-Free Vegan Milk India in March 2024. People with lactose intolerance benefit from taking lactose-free milk and its products. This condition is common, especially among adults. The body produces an enzyme called lactase that helps it digest lactose properly. In people suffering from this condition, the production of adequate amounts of lactase is stopped by their bodies, thus causing them to experience symptoms such as bloating, cramps, diarrhea, and nausea.
Founder and COO of Drupe Food India discussed the topic by saying, “Drupe is the first natural real almond milk made at a plant in bottles without preservatives, sugar or additives or any artificial flavor substance.” According to these rules, the nutritive content of a meal may be degraded by cooking methods (such as applying sugar) but make it taste better at 50%.
In February 2024, Nestlé SA, a Swiss multinational company, unveiled its initial precision fermentation dairy protein powder known as Better Whey, which does not have animals or lactose and is a whey isolate product under Orgain brand (it had acquired a majority stake in early 2022 for expanding its presence in functional nutrition market). Customers can buy Orgain’s Better Whey via the company’s website. There will also be a small pilot test in-store nationwide across the United States; however, no further details are available yet, according to a Green Queen interview with Nestlé representative. It costs $29.99 per 13.3-ounce tub ($2.3 per ounce). The plant whey-based variety of the brand, which offers similar amount of protein per serving goes for around $1.2 per oz, whereas the second one made from fermented whey could be almost double at approximately $2 per ounce.
In November 2022, Nestlé’s Nescafé Dolce Gusto launched its “Neo,” a next-generation coffee machines and pods. Neo is an exceptional blend of home-based experience in coffeehouses through the highest quality blends that combine both up to date technology as well as sustainability.
In October 2022, Nestle had pronounced their intentions to buy Starbucks’ Seattle's Best Coffee brand. This acquisition will facilitate profitable growth in coffee business by Nestle and strengthen Global Coffee Alliance allowing them both to focus on their areas of specialization.
Lactose intolerance is a medical condition identified by lactase (lactose digesting enzyme) deficiency within the patient’s body. As a result, lactose remains intact and unabsorbed producing various ill-effects such as flatulence, bloating, and abdominal pains. Four types of lactose intolerances are identified, namely, primary lactase deficiency, secondary lactase deficiency, congenital lactase deficiency, and developmental lactase deficiency. Secondary lactase deficiency mainly occurs due to irritable bowel syndrome (IBS), gastroenteritis, Crohn's disease, ulcerative colitis, celiac disease, chemotherapy, and antibiotics. As per the study by the Journal of Health, Population, and Nutrition in 2017, the prevalence of lactose intolerance was significantly higher in IBS-D patients compared to healthy individuals. In this study, some eligible IBS-D patients and healthy individuals were enrolled. In the enrolled individuals, lactose malabsorption was diagnosed by a lactose hydrogen breath test (HBT), and lactose intolerance-related symptoms were monitored for eight hours following lactose administration. It was found that the prevalence of lactose malabsorption was 72% in IBS patients and 60% in healthy individuals.
A study published in the Advances in Clinical and Experimental Medicine in 2015 also showed that the incidence rate of lactose malabsorption with lactose intolerance was 27.16% in pediatric patients with gastrointestinal diseases. Moreover, the highest occurrence was 47.83% in IBS, and the lowest was 15.78% of ulcer disease. IBS represents a significant burden on the US and globally, with an estimated prevalence rate of 14%. From all the information, it is observed that the escalating cases of IBS and other gastrointestinal disorders would boost the US lactose intolerance treatment market
Global Lactose Intolerance Treatment Market is segmented into Type, Treatment, Form, and End User.
Global Lactose Intolerance Treatment Market based on the type has been segmented into primary lactose intolerance, secondary lactose intolerance, congenital lactose intolerance. Primary lactose intolerance dominated the market in 2022. Primary lactose intolerance has a high prevalence rate as compared to others.
The global lactose intolerance treatment market, by treatment, has been segmented into food supplements, enzyme lactase supplements, probiotics. The food supplements segment held the largest market share in 2022. The growing adoption of Lactose-free products is fueling the market growth of this segment.
Based on form, the market has been segmented into powder, liquid, tablet. The powder segment dominated the market in 2022.
The global lactose intolerance treatment market, by end user, has been segmented into homecare, hospitals and clinics, and others. The homecare held the largest share with a CAGR of 6.04%.
Global Lactose Intolerance Treatment Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas spearheaded the market in 2022 and is likely to continue to command during the assessment period. This is attributed to the rising incidence of lactose intolerance and product innovation.
The European lactose intolerance treatment market has been divided into Western Europe and Eastern Europe. The Western Europe lactose intolerance treatment market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. Europe would follow the Americas during the forecast period owing to the presence of favorable government initiatives, research and development activities, and business expansions by major players.
The lactose intolerance treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Asia-Pacific is expected to exhibit the highest market growth potential during the forecast period due to increasing healthcare expenditure, distribution of chilled dairy products in China, India, and Australia, and increasing population suffering from lactose intolerance.
The Middle East & Africa lactose intolerance treatment market is segmented into the Middle East and Africa. The Middle East and Africa are highly obsolescence with per capita spend on dairy at just USD 25 per head, the lowest in the world. The underdeveloped infrastructural chain of the region makes it very difficult for the manufacturers to reach their consumers. However, if the affordability rate improves, the growth of the market would be even more dynamic.
The Prominent Players in the Global Lactose Intolerance Treatment Market are:
Some of the key strategies adopted by players operating in the global lactose intolerance treatment market were joint ventures, FDA approvals, acquisitions, expansions, and collaborations, among others.
Available Additional Customizations
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)